Anika Therapeutics Q4 Earnings Call Highlights

Profitability improved in the quarter, with GAAP gross margin rising to 63% from 56% a year earlier, reflecting a more favorable mix and higher volumes that improved manufacturing throughput and productivity. Operating expenses were $18.5 million , up from $17.8 million , with SG&A increasing on higher sales and marketing spending tied primarily to Integrity growth, while R&D held flat at $6.5 million .OEM channel revenue was $17.3 million , down 12% year-over-year. Management pointed to lower year-over-yea ...